- Home
- NSIT vs NUVL Comparison
NSIT vs NUVL Comparison
Compare NSIT & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSIT
- NUVL
- Stock Information
- Founded
- NSIT 1988
- NUVL 2017
- Country
- NSIT United States
- NUVL United States
- Employees
- NSIT N/A
- NUVL N/A
- Industry
- NSIT EDP Services
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- NSIT Technology
- NUVL Health Care
- Exchange
- NSIT Nasdaq
- NUVL Nasdaq
- Market Cap
- NSIT 5.5B
- NUVL 5.6B
- IPO Year
- NSIT 1995
- NUVL 2021
- Fundamental
- Price
- NSIT $149.99
- NUVL $70.74
- Analyst Decision
- NSIT Buy
- NUVL Strong Buy
- Analyst Count
- NSIT 4
- NUVL 10
- Target Price
- NSIT $212.50
- NUVL $113.10
- AVG Volume (30 Days)
- NSIT 407.8K
- NUVL 557.5K
- Earning Date
- NSIT 05-01-2025
- NUVL 05-08-2025
- Dividend Yield
- NSIT N/A
- NUVL N/A
- EPS Growth
- NSIT N/A
- NUVL N/A
- EPS
- NSIT 6.55
- NUVL N/A
- Revenue
- NSIT $8,701,698,000.00
- NUVL N/A
- Revenue This Year
- NSIT $3.60
- NUVL N/A
- Revenue Next Year
- NSIT $5.24
- NUVL N/A
- P/E Ratio
- NSIT $23.30
- NUVL N/A
- Revenue Growth
- NSIT N/A
- NUVL N/A
- 52 Week Low
- NSIT $146.56
- NUVL $61.80
- 52 Week High
- NSIT $228.07
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- NSIT 39.33
- NUVL 35.57
- Support Level
- NSIT $152.33
- NUVL $71.95
- Resistance Level
- NSIT $160.68
- NUVL $77.93
- Average True Range (ATR)
- NSIT 4.54
- NUVL 3.04
- MACD
- NSIT 0.04
- NUVL -0.16
- Stochastic Oscillator
- NSIT 4.21
- NUVL 24.64
About NSIT Insight Enterprises Inc.
Insight Enterprises Inc is a Fortune IT provider engaged in helping businesses of all sizes, large enterprises, governments, schools, and healthcare organizations. The company has three geographic operating segments: North America, EMEA, and APAC. It generates maximum revenue from the North America segment. The company provides digital innovation, cloud/data center transformation, connected workforce, and supply chain optimization solutions and services.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.